Shahnawaz, Mohammad
Mukherjee, Abhisek
Pritzkow, Sandra
Mendez, Nicolas
Rabadia, Prakruti
Liu, Xiangan
Hu, Bo
Schmeichel, Ann
Singer, Wolfgang
Wu, Gang
Tsai, Ah-Lim
Shirani, Hamid
Nilsson, K. Peter R.
Low, Phillip A.
Soto, Claudio
Article History
Received: 14 November 2018
Accepted: 10 January 2020
First Online: 5 February 2020
Competing interests
: C.S. and M.S. are inventors on patent applications (US20160077111, WO2016040905, EP3191599A1, US20160077112 and WO2016040907) for the use of PMCA technology for high-sensitive detection of α-syn aggregates in patients affected by synucleinopathies. These applications were filed by the University of Texas Health Science Center at Houston and Amprion Inc. C.S. is an inventor on several patents related to PMCA technology and is a Founder, Chief Scientific Officer and Member of the Board of Directors of Amprion Inc, a biotechnology company that focuses on the commercial use of PMCA (RT-QuIC) for high-sensitivity detection of misfolded protein aggregates that are implicated in a variety of neurodegenerative diseases. The University of Texas Health Science Center at Houston owns some patent applications related to the PMCA (RT-QuIC) technology that have been licensed to Amprion Inc.